Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Durvalumab market report explains the definition, types, applications, major countries, and major players of the Durvalumab market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
Medimmune (AstraZeneca)
By Type:
24mL Injection
10mL Injection
By End-User:
Locally Advanced Urothelial Carcinoma
Metastatic Urothelial Carcinoma
Other
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Durvalumab Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Durvalumab Outlook to 2028- Original Forecasts
-
2.2 Durvalumab Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Durvalumab Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Durvalumab Market- Recent Developments
-
6.1 Durvalumab Market News and Developments
-
6.2 Durvalumab Market Deals Landscape
7 Durvalumab Raw Materials and Cost Structure Analysis
-
7.1 Durvalumab Key Raw Materials
-
7.2 Durvalumab Price Trend of Key Raw Materials
-
7.3 Durvalumab Key Suppliers of Raw Materials
-
7.4 Durvalumab Market Concentration Rate of Raw Materials
-
7.5 Durvalumab Cost Structure Analysis
-
7.5.1 Durvalumab Raw Materials Analysis
-
7.5.2 Durvalumab Labor Cost Analysis
-
7.5.3 Durvalumab Manufacturing Expenses Analysis
8 Global Durvalumab Import and Export Analysis (Top 10 Countries)
-
8.1 Global Durvalumab Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Durvalumab Export by Region (Top 10 Countries) (2017-2028)
9 Global Durvalumab Market Outlook by Types and Applications to 2022
-
9.1 Global Durvalumab Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global 24mL Injection Consumption and Growth Rate (2017-2022)
-
9.1.2 Global 10mL Injection Consumption and Growth Rate (2017-2022)
-
9.2 Global Durvalumab Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Locally Advanced Urothelial Carcinoma Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Metastatic Urothelial Carcinoma Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Other Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Durvalumab Market Analysis and Outlook till 2022
-
10.1 Global Durvalumab Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Durvalumab Consumption (2017-2022)
-
10.2.2 Canada Durvalumab Consumption (2017-2022)
-
10.2.3 Mexico Durvalumab Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Durvalumab Consumption (2017-2022)
-
10.3.2 UK Durvalumab Consumption (2017-2022)
-
10.3.3 Spain Durvalumab Consumption (2017-2022)
-
10.3.4 Belgium Durvalumab Consumption (2017-2022)
-
10.3.5 France Durvalumab Consumption (2017-2022)
-
10.3.6 Italy Durvalumab Consumption (2017-2022)
-
10.3.7 Denmark Durvalumab Consumption (2017-2022)
-
10.3.8 Finland Durvalumab Consumption (2017-2022)
-
10.3.9 Norway Durvalumab Consumption (2017-2022)
-
10.3.10 Sweden Durvalumab Consumption (2017-2022)
-
10.3.11 Poland Durvalumab Consumption (2017-2022)
-
10.3.12 Russia Durvalumab Consumption (2017-2022)
-
10.3.13 Turkey Durvalumab Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Durvalumab Consumption (2017-2022)
-
10.4.2 Japan Durvalumab Consumption (2017-2022)
-
10.4.3 India Durvalumab Consumption (2017-2022)
-
10.4.4 South Korea Durvalumab Consumption (2017-2022)
-
10.4.5 Pakistan Durvalumab Consumption (2017-2022)
-
10.4.6 Bangladesh Durvalumab Consumption (2017-2022)
-
10.4.7 Indonesia Durvalumab Consumption (2017-2022)
-
10.4.8 Thailand Durvalumab Consumption (2017-2022)
-
10.4.9 Singapore Durvalumab Consumption (2017-2022)
-
10.4.10 Malaysia Durvalumab Consumption (2017-2022)
-
10.4.11 Philippines Durvalumab Consumption (2017-2022)
-
10.4.12 Vietnam Durvalumab Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Durvalumab Consumption (2017-2022)
-
10.5.2 Colombia Durvalumab Consumption (2017-2022)
-
10.5.3 Chile Durvalumab Consumption (2017-2022)
-
10.5.4 Argentina Durvalumab Consumption (2017-2022)
-
10.5.5 Venezuela Durvalumab Consumption (2017-2022)
-
10.5.6 Peru Durvalumab Consumption (2017-2022)
-
10.5.7 Puerto Rico Durvalumab Consumption (2017-2022)
-
10.5.8 Ecuador Durvalumab Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Durvalumab Consumption (2017-2022)
-
10.6.2 Kuwait Durvalumab Consumption (2017-2022)
-
10.6.3 Oman Durvalumab Consumption (2017-2022)
-
10.6.4 Qatar Durvalumab Consumption (2017-2022)
-
10.6.5 Saudi Arabia Durvalumab Consumption (2017-2022)
-
10.6.6 United Arab Emirates Durvalumab Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Durvalumab Consumption (2017-2022)
-
10.7.2 South Africa Durvalumab Consumption (2017-2022)
-
10.7.3 Egypt Durvalumab Consumption (2017-2022)
-
10.7.4 Algeria Durvalumab Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Durvalumab Consumption (2017-2022)
-
10.8.2 New Zealand Durvalumab Consumption (2017-2022)
11 Global Durvalumab Competitive Analysis
-
11.1 Medimmune (AstraZeneca)
-
11.1.1 Medimmune (AstraZeneca) Company Details
-
11.1.2 Medimmune (AstraZeneca) Durvalumab Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 Medimmune (AstraZeneca) Durvalumab Main Business and Markets Served
-
11.1.4 Medimmune (AstraZeneca) Durvalumab Product Portfolio
-
11.1.5 Recent Research and Development Strategies
12 Global Durvalumab Market Outlook by Types and Applications to 2028
-
12.1 Global Durvalumab Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global 24mL Injection Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global 10mL Injection Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Durvalumab Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Locally Advanced Urothelial Carcinoma Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Metastatic Urothelial Carcinoma Consumption Forecast and Growth Rate (2022-2028)
-
12.2.3 Global Other Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Durvalumab Market Analysis and Outlook to 2028
-
13.1 Global Durvalumab Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Durvalumab Consumption Forecast (2022-2028)
-
13.2.2 Canada Durvalumab Consumption Forecast (2022-2028)
-
13.2.3 Mexico Durvalumab Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Durvalumab Consumption Forecast (2022-2028)
-
13.3.2 UK Durvalumab Consumption Forecast (2022-2028)
-
13.3.3 Spain Durvalumab Consumption Forecast (2022-2028)
-
13.3.4 Belgium Durvalumab Consumption Forecast (2022-2028)
-
13.3.5 France Durvalumab Consumption Forecast (2022-2028)
-
13.3.6 Italy Durvalumab Consumption Forecast (2022-2028)
-
13.3.7 Denmark Durvalumab Consumption Forecast (2022-2028)
-
13.3.8 Finland Durvalumab Consumption Forecast (2022-2028)
-
13.3.9 Norway Durvalumab Consumption Forecast (2022-2028)
-
13.3.10 Sweden Durvalumab Consumption Forecast (2022-2028)
-
13.3.11 Poland Durvalumab Consumption Forecast (2022-2028)
-
13.3.12 Russia Durvalumab Consumption Forecast (2022-2028)
-
13.3.13 Turkey Durvalumab Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Durvalumab Consumption Forecast (2022-2028)
-
13.4.2 Japan Durvalumab Consumption Forecast (2022-2028)
-
13.4.3 India Durvalumab Consumption Forecast (2022-2028)
-
13.4.4 South Korea Durvalumab Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Durvalumab Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Durvalumab Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Durvalumab Consumption Forecast (2022-2028)
-
13.4.8 Thailand Durvalumab Consumption Forecast (2022-2028)
-
13.4.9 Singapore Durvalumab Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Durvalumab Consumption Forecast (2022-2028)
-
13.4.11 Philippines Durvalumab Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Durvalumab Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Durvalumab Consumption Forecast (2022-2028)
-
13.5.2 Colombia Durvalumab Consumption Forecast (2022-2028)
-
13.5.3 Chile Durvalumab Consumption Forecast (2022-2028)
-
13.5.4 Argentina Durvalumab Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Durvalumab Consumption Forecast (2022-2028)
-
13.5.6 Peru Durvalumab Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Durvalumab Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Durvalumab Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Durvalumab Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Durvalumab Consumption Forecast (2022-2028)
-
13.6.3 Oman Durvalumab Consumption Forecast (2022-2028)
-
13.6.4 Qatar Durvalumab Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Durvalumab Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Durvalumab Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Durvalumab Consumption Forecast (2022-2028)
-
13.7.2 South Africa Durvalumab Consumption Forecast (2022-2028)
-
13.7.3 Egypt Durvalumab Consumption Forecast (2022-2028)
-
13.7.4 Algeria Durvalumab Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Durvalumab Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Durvalumab Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Durvalumab
-
Figure of Durvalumab Picture
-
Table Global Durvalumab Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Durvalumab Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global 24mL Injection Consumption and Growth Rate (2017-2022)
-
Figure Global 10mL Injection Consumption and Growth Rate (2017-2022)
-
Figure Global Locally Advanced Urothelial Carcinoma Consumption and Growth Rate (2017-2022)
-
Figure Global Metastatic Urothelial Carcinoma Consumption and Growth Rate (2017-2022)
-
Figure Global Other Consumption and Growth Rate (2017-2022)
-
Figure Global Durvalumab Consumption by Country (2017-2022)
-
Table North America Durvalumab Consumption by Country (2017-2022)
-
Figure United States Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure Canada Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure Mexico Durvalumab Consumption and Growth Rate (2017-2022)
-
Table Europe Durvalumab Consumption by Country (2017-2022)
-
Figure Germany Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure UK Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure Spain Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure Belgium Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure France Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure Italy Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure Denmark Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure Finland Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure Norway Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure Sweden Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure Poland Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure Russia Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure Turkey Durvalumab Consumption and Growth Rate (2017-2022)
-
Table APAC Durvalumab Consumption by Country (2017-2022)
-
Figure China Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure Japan Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure India Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure South Korea Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure Thailand Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure Singapore Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure Philippines Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Durvalumab Consumption and Growth Rate (2017-2022)
-
Table South America Durvalumab Consumption by Country (2017-2022)
-
Figure Brazil Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure Colombia Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure Chile Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure Argentina Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure Peru Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Durvalumab Consumption and Growth Rate (2017-2022)
-
Table GCC Durvalumab Consumption by Country (2017-2022)
-
Figure Bahrain Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure Oman Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure Qatar Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Durvalumab Consumption and Growth Rate (2017-2022)
-
Table Africa Durvalumab Consumption by Country (2017-2022)
-
Figure Nigeria Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure South Africa Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure Egypt Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure Algeria Durvalumab Consumption and Growth Rate (2017-2022)
-
Table Oceania Durvalumab Consumption by Country (2017-2022)
-
Figure Australia Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Durvalumab Consumption and Growth Rate (2017-2022)
-
Table Medimmune (AstraZeneca) Company Details
-
Table Medimmune (AstraZeneca) Durvalumab Sales, Price, Value and Gross Profit (2017-2022)
-
Table Medimmune (AstraZeneca) Durvalumab Main Business and Markets Served
-
Table Medimmune (AstraZeneca) Durvalumab Product Portfolio
-
Figure Global 24mL Injection Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global 10mL Injection Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Locally Advanced Urothelial Carcinoma Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Metastatic Urothelial Carcinoma Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Other Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Durvalumab Consumption Forecast by Country (2022-2028)
-
Table North America Durvalumab Consumption Forecast by Country (2022-2028)
-
Figure United States Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Durvalumab Consumption Forecast by Country (2022-2028)
-
Figure Germany Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Durvalumab Consumption Forecast by Country (2022-2028)
-
Figure China Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Durvalumab Consumption Forecast by Country (2022-2028)
-
Figure Brazil Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Durvalumab Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Durvalumab Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Durvalumab Consumption Forecast by Country (2022-2028)
-
Figure Australia Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
